Use the hyperlinks, where available to access additional clinical trial information.
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
Australasian Gastro-Intestinal Trials Group (AGITG)
Participants in this trial will be randomised into one of two treatment arms. In Experimental Arm 1, patients will receive Nivolumab (10MG/ML) and BNC105 intravenously as a sterile solution. In Experimental Arm 2, patients will recieve nivolumab and oral capsules of BBI-608.